FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2007679040> ?p ?o ?g. }

• W2007679040 abstract "Brain tumors are the most common solid pediatric malignancy. For high-grade, recurrent, or refractory pediatric brain tumors, radiation therapy (XRT) is an integral treatment modality. In the era of personalized cancer therapy, molecularly targeted agents have been designed to inhibit pathways critical to tumorigenesis. Our evolving knowledge of genetic aberrations in pediatric gliomas is being exploited with the use of specific targeted inhibitors. These agents are additionally being combined with XRT to increase the efficacy and duration of local control. In this review, we discuss novel agents targeting three different pathways in gliomas, and their potential combination with XRT. BRAF is a serine/threonine kinase in the RAS/RAF/MAPK kinase pathway, which is integral to cellular division, survival, and metabolism. Two-thirds of pilocytic astrocytomas, a low-grade pediatric glioma, contain a translocation within the BRAF gene called KIAA1549:BRAF that causes an overactivation of the MEK/MAPK signaling cascade. In vitro and in vivo data support the use of MEK or mammalian target of rapamycin (mTOR) inhibitors in low-grade gliomas expressing this translocation. Additionally, 15-20% of high-grade pediatric gliomas express BRAF V600E, an activating mutation of the BRAF gene. Pre-clinical in vivo and in vitro data in BRAF V600E gliomas demonstrate dramatic cooperation between XRT and small molecule inhibitors of BRAF V600E. Another major signaling cascade that plays a role in pediatric glioma pathogenesis is the PI3-kinase (PI3K)/mTOR pathway, known to be upregulated in the majority of high- and low-grade pediatric gliomas. Dual PI3K/mTOR inhibitors are in clinical trials for adult high-grade gliomas and are poised to enter studies of pediatric tumors. Finally, many brain tumors express potent stimulators of angiogenesis that render them refractory to treatment. An analog of thalidomide, CC-5103 increases the secretion of critical cytokines of the tumor microenvironment, including IL-2, IFN-γ, TNF-α, and IL-10, and is currently being evaluated in clinical trials for the treatment of recurrent or refractory pediatric central nervous system tumors. In summary, several targeted inhibitors with radiation are currently under investigation in both translational bench research and early clinical trials. This review article summarizes the molecular rationale for, and the pre-clinical data supporting the combinations of these targeted agents with other anti-cancer agents and XRT in pediatric gliomas. In many cases, parallels are drawn to molecular mechanisms and targeted inhibitors of adult gliomas. We additionally discuss the potential mechanisms underlying the efficacy of these agents." @default.
• W2007679040 created "2016-06-24" @default.
• W2007679040 creator A5011597554 @default.
• W2007679040 creator A5085032736 @default.
• W2007679040 date "2013-01-01" @default.
• W2007679040 modified "2023-10-14" @default.
• W2007679040 title "The Combination of Novel Targeted Molecular Agents and Radiation in the Treatment of Pediatric Gliomas" @default.
• W2007679040 cites W1519299662 @default.
• W2007679040 cites W1529336528 @default.
• W2007679040 cites W1556414207 @default.
• W2007679040 cites W1646439986 @default.
• W2007679040 cites W167690879 @default.
• W2007679040 cites W1859470153 @default.
• W2007679040 cites W1866745781 @default.
• W2007679040 cites W1912612607 @default.
• W2007679040 cites W1965612197 @default.
• W2007679040 cites W1965766554 @default.
• W2007679040 cites W1971361765 @default.
• W2007679040 cites W1984569056 @default.
• W2007679040 cites W1984621921 @default.
• W2007679040 cites W1991246209 @default.
• W2007679040 cites W1993745402 @default.
• W2007679040 cites W2003524270 @default.
• W2007679040 cites W2009964860 @default.
• W2007679040 cites W2012849046 @default.
• W2007679040 cites W2014881369 @default.
• W2007679040 cites W2017183045 @default.
• W2007679040 cites W2020773732 @default.
• W2007679040 cites W2023041438 @default.
• W2007679040 cites W2023234343 @default.
• W2007679040 cites W2025106701 @default.
• W2007679040 cites W2031621781 @default.
• W2007679040 cites W2035495486 @default.
• W2007679040 cites W2036063985 @default.
• W2007679040 cites W2036198992 @default.
• W2007679040 cites W2037529711 @default.
• W2007679040 cites W2040273493 @default.
• W2007679040 cites W2040472849 @default.
• W2007679040 cites W2057517953 @default.
• W2007679040 cites W2060827471 @default.
• W2007679040 cites W2065155886 @default.
• W2007679040 cites W2069619905 @default.
• W2007679040 cites W2071752743 @default.
• W2007679040 cites W2084956980 @default.
• W2007679040 cites W2085163752 @default.
• W2007679040 cites W2091100650 @default.
• W2007679040 cites W2093334927 @default.
• W2007679040 cites W2096287682 @default.
• W2007679040 cites W2105602306 @default.
• W2007679040 cites W2106494998 @default.
• W2007679040 cites W2109227311 @default.
• W2007679040 cites W2109996739 @default.
• W2007679040 cites W2110830894 @default.
• W2007679040 cites W2112757377 @default.
• W2007679040 cites W2112785522 @default.
• W2007679040 cites W2116362236 @default.
• W2007679040 cites W2118677643 @default.
• W2007679040 cites W2119338502 @default.
• W2007679040 cites W2124664680 @default.
• W2007679040 cites W2126062426 @default.
• W2007679040 cites W2127003779 @default.
• W2007679040 cites W2127063807 @default.
• W2007679040 cites W2127504482 @default.
• W2007679040 cites W2128542677 @default.
• W2007679040 cites W2129554457 @default.
• W2007679040 cites W2130743512 @default.
• W2007679040 cites W2134992662 @default.
• W2007679040 cites W2136849863 @default.
• W2007679040 cites W2146267855 @default.
• W2007679040 cites W2149576862 @default.
• W2007679040 cites W2149890572 @default.
• W2007679040 cites W2151291770 @default.
• W2007679040 cites W2152012915 @default.
• W2007679040 cites W2152083763 @default.
• W2007679040 cites W2155162253 @default.
• W2007679040 cites W2159331778 @default.
• W2007679040 cites W2162251295 @default.
• W2007679040 cites W2165534057 @default.
• W2007679040 cites W2166262263 @default.
• W2007679040 cites W2169004576 @default.
• W2007679040 cites W2170084272 @default.
• W2007679040 cites W2171512544 @default.
• W2007679040 cites W2319442761 @default.
• W2007679040 cites W2187100913 @default.
• W2007679040 doi "https://doi.org/10.3389/fonc.2013.00110" @default.
• W2007679040 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3650671" @default.
• W2007679040 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/23717811" @default.
• W2007679040 hasPublicationYear "2013" @default.
• W2007679040 type Work @default.
• W2007679040 sameAs 2007679040 @default.
• W2007679040 citedByCount "34" @default.
• W2007679040 countsByYear W20076790402012 @default.
• W2007679040 countsByYear W20076790402013 @default.
• W2007679040 countsByYear W20076790402014 @default.
• W2007679040 countsByYear W20076790402015 @default.
• W2007679040 countsByYear W20076790402016 @default.
• W2007679040 countsByYear W20076790402017 @default.
• W2007679040 countsByYear W20076790402018 @default.
• W2007679040 countsByYear W20076790402019 @default.
• W2007679040 countsByYear W20076790402020 @default.

• next